Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Small Cell Lung Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
All Articles
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Breast Cancer
,
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Multiple Myeloma
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
By
Loretta Fala
FDA Approvals, News & Updates
,
Leukemia
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
By
Lisa A. Raedler, PhD, RPh
Breast Cancer
,
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Page 212 of 298
209
210
211
212
213
214
215
